Phase 3 Liver Cancer Trial, Recruiting (NCT06109272)

Phase 3 Liver Cancer Trial, Recruiting NCT06109272 Sponsor: AbbVie Condition: Liver Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06109272 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Liver Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with liver cancer (hepatocellular carcinoma) that has spread or cannot be removed by surgery, confirmed by a biopsy, lab test, or by standard medical guidelines if you also have liver scarring (cirrhosis).
Your liver cancer is classified as Stage B or C using a system called the Barcelona Clinic Liver Cancer (BCLC) staging scale (confirm with trial site).
Your overall liver health falls within a certain range, measured by a scoring system called Child-Pugh — specifically a score of 5, 6, or 7 (confirm with trial site).
You are generally able to carry out daily activities with little or no limitation, rated 0 or 1 on a standard scale doctors use to measure how well a patient can function.

Who may not be able to join:

You have already received systemic (whole-body) treatment, such as chemotherapy or targeted therapy, for your liver cancer.
You have cancer that has spread to the brain or spinal cord (central nervous system) and it is causing symptoms, has not been treated, or is getting worse.
You have had, or currently have, any other type of cancer besides liver cancer (hepatocellular carcinoma).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 7 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06109272

Sponsor: AbbVie

Phase: Phase 3

Status: Recruiting

Condition: Liver Cancer

Trial contact: 844-663-3742

More information: https://clinicaltrials.gov/study/NCT06109272

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with liver cancer (hepatocellular carcinoma) that has spread or cannot be removed by surgery, confirmed by a biopsy, lab test, or by standard medical guidelines if you also have liver scarring (cirrhosis).
Your liver cancer is classified as Stage B or C using a system called the Barcelona Clinic Liver Cancer (BCLC) staging scale (confirm with trial site).
Your overall liver health falls within a certain range, measured by a scoring system called Child-Pugh — specifically a score of 5, 6, or 7 (confirm with trial site).
You are generally able to carry out daily activities with little or no limitation, rated 0 or 1 on a standard scale doctors use to measure how well a patient can function.

Who may not be able to join:

You have already received systemic (whole-body) treatment, such as chemotherapy or targeted therapy, for your liver cancer.
You have cancer that has spread to the brain or spinal cord (central nervous system) and it is causing symptoms, has not been treated, or is getting worse.
You have had, or currently have, any other type of cancer besides liver cancer (hepatocellular carcinoma).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 7 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

AbbVie

Registry

ClinicalTrials.gov

Start date

11 January 2024

Est. completion

1 September 2030

Where this trial is recruiting

🇫🇷 France 🇮🇹 Italy Puerto Rico 🇪🇸 Spain 🇹🇼 Taiwan 🇺🇸 United States

Primary endpoints

Stage 1: Best Overall Response (BOR) per Investigator; Stage 2: Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov